| ID | Sequence | Length | GC content |
|---|---|---|---|
| AGUUACAGGGAGCACCACCAGGGAACAUCUCGGGGAGCCUGGUUGGAAG… | 1828 nt | 0.4644 | |
| GCCCCCUUGCUUCGCGCGCGCGCAGCCCCGCAGCGCAGCUUUGGCGGCG… | 1783 nt | 0.4689 | |
| AGUUACAGGGAGCACCACCAGGGAACAUCUCGGGGAGCCUGGUUGGAAG… | 1824 nt | 0.4638 | |
| AGUUACAGGGAGCACCACCAGGGAACAUCUCGGGGAGCCUGGUUGGAAG… | 592 nt | 0.5270 | |
| GCCCCCUUGCUUCGCGCGCGCGCAGCCCCGCAGCGCAGCUUUGGCGGCG… | 1779 nt | 0.4694 | |
| GCGCGCCUCCGUCGCUCGGCCCAGUGCGUUCGGCCUCACGCCCAGCGCU… | 1714 nt | 0.4638 |
This gene encodes an integral membrane protein that is a major component of myelin in the peripheral nervous system. Studies suggest two alternately used promoters drive tissue-specific expression. Various mutations of this gene are causes of Charcot-Marie-Tooth disease Type IA, Dejerine-Sottas syndrome, and hereditary neuropathy with liability to pressure palsies. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]
A study in humans characterized the platelet transcriptome via RNA-seq in patients with acute myocardial infarction (MI) and identified the PMP22 as having increased expression in platelets from ST-segment elevation MI (STEMI) patients compared to non-STEMI (NSTEMI) patients [Eicher et al. DOI:10.3109/09537104.2015.1083543]. A study in mice demonstrated that the PMP22 transcript, a pro-apoptotic regulator, increased in abundance within 0.5 hours postmortem [Pozhitkov et al. DOI:10.1098/rsob.160267].